Search

Your search keyword '"van Oosten B"' showing total 98 results

Search Constraints

Start Over You searched for: Author "van Oosten B" Remove constraint Author: "van Oosten B"
98 results on '"van Oosten B"'

Search Results

1. Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial

2. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

5. The role of appraisal and coping style in relation with societal participation in fatigued patients with multiple sclerosis: a cross-sectional multiple mediator analysis

8. Serum neurofilaments as candidate biomarkers of natalizumab-associated PML

9. Three distinct physical behavior types in fatigued patients with multiple sclerosis

10. Fourth meeting of the European Neurological Society 25–29 June 1994 Barcelona, Spain: Abstracts of Symposia and free communications

11. Energy Conservation Management for People With Multiple Sclerosis-Related Fatigue: Who Benefits?

13. Second IVIg course in Guillain-Barre syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial

16. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

17. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

18. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

19. Effectiveness of energy conservation management on fatigue and participation in multiple sclerosis: A randomized controlled trial

22. Een hangend ooglid; diagnostiek op basis van een algoritme

23. New diagnostic criteria for multiple sclerosis in clinical practice

24. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis

26. PROBLEMEN BIJ HET ONTWENNEN VAN KUNSTMATIGE VENTILATIE: 'MOTOR-NEURON DISEASE'

30. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis

31. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial

38. Effect of rimonabant on weight reduction and cardiovascular risk.

39. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

41. The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis.

42. Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.

43. Validation of the Charlson Comorbidity Index for the prediction of 30-day and 1-year mortality among patients who underwent hip fracture surgery.

44. Successful treatment of respiratory failure in Hirayama disease.

45. The interaction and orientation of Peptide KL 4 in model membranes.

46. Diffuse alveolar hemorrhage as an early complication of alemtuzumab treatment: A case report of a multiple sclerosis patient and an overview of 14 cases.

47. DNA surface exploration and operator bypassing during target search.

48. Response: Brain miliary enhancement.

49. A tumefactive demyelinating lesion in a person with MS after five years of fingolimod.

50. Brain miliary enhancement.

Catalog

Books, media, physical & digital resources